Literature DB >> 9283646

Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs.

W Mayrink1, O Genaro, J C Silva, R T da Costa, W L Tafuri, V P Toledo, A R da Silva, A B Reis, P Williams, P W da Costa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9283646     DOI： 10.1590/s0074-02761996000600006

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN： 0074-0276            Impact factor:   2.743


× No keyword cloud information.
  17 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

Review 2.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.

Authors:  Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Henrique Gama Ker; Nádia das Dores Moreira; Fernando Augusto Siqueira Mathias; Jamille Mirelle de Oliveira Cardoso; Nelder Figueiredo Gontijo; Oscar Bruna-Romero; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Rodrigo Corrêa-Oliveira; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  Parasit Vectors       Date:  2014-02-07       Impact factor: 3.876

4.  Mapping B-cell epitopes for the peroxidoxin of Leishmania (Viannia) braziliensis and its potential for the clinical diagnosis of tegumentary and visceral leishmaniasis.

Authors:  Daniel Menezes-Souza; Tiago Antônio de Oliveira Mendes; Ronaldo Alves Pinto Nagem; Thaís Teodoro de Oliveira Santos; Ana Luíza Teixeira Silva; Marcelo Matos Santoro; Silvio Fernando Guimarães de Carvalho; Eduardo Antônio Ferraz Coelho; Daniella Castanheira Bartholomeu; Ricardo Toshio Fujiwara
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

Review 5.  Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

Authors:  Nicky Didwania; Md Shadab; Abdus Sabur; Nahid Ali
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

6.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

7.  Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano-Souza; Wendel Coura-Vital; Samuel Leôncio Braga; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Marta de Lana; Nelder Figueiredo Gontijo; Marcos José Marques; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

8.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

9.  The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.

Authors:  Virginie Martin; Ioannis Vouldoukis; Javier Moreno; David McGahie; Sylvie Gueguen; Anne-Marie Cuisinier
Journal:  Vet Res       Date:  2014-06-25       Impact factor: 3.683

10.  Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin.

Authors:  Juliana Vitoriano-Souza; Alexandre B Reis; Nádia D Moreira; Rodolfo C Giunchetti; Rodrigo Correa-Oliveira; Cláudia M Carneiro
Journal:  Vaccine       Date:  2008-05-22       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.